SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ — Brightonix Imaging, a global leader in cutting-edge medical imaging technology, proudly announces FDA clearance for its flagship product, the PHAROS PET Scanner, in the United States. This achievement signifies a breakthrough in nuclear imaging, positioning Brightonix at the forefront of medical innovation. Based in South Korea, the company continues to revolutionize the industry with advanced technology.
CEO, Mr. Kim Jong, expressed his excitement, stating, ‘Receiving FDA clearance for the PHAROS PET Scanner is a significant milestone for Brightonix Imaging. We are thrilled to bring our cutting-edge technology to the US market, enhancing precision and efficiency in medical imaging.’ This endorsement from the FDA underscores Brightonix’s commitment to delivering top-notch healthcare solutions worldwide.
The PHAROS PET Scanner’s approval for commercial distribution in the United States solidifies Brightonix Imaging’s reputation as a global leader in medical imaging technology. With a focus on innovation and accuracy, the company sets a new standard for nuclear imaging. The advanced features of the PHAROS PET Scanner promise enhanced performance and quality in medical diagnostics, catering to the evolving needs of healthcare professionals and patients.
Brightonix Imaging’s dedication to excellence is evident in its FDA clearance for the PHAROS PET Scanner, a milestone that showcases the company’s commitment to advancing healthcare technology. By securing approval for commercial distribution in the US, Brightonix paves the way for a future of cutting-edge medical imaging solutions that prioritize precision and efficiency. As a key player in the industry, Brightonix continues to drive innovation and shape the landscape of medical imaging.
Deixe um comentário